Key Takeaway: Co-Dx™ has been awarded $1.2 million by the NIH's RADx Tech program to advance its upper respiratory panel. This multiplex test will detect influenza A/B, COVID-19, and respiratory syncytial virus using the Co-Dx PCR Home™ Testing Platform. The funding will aid in completing the assay's development and preparing for clinical trials.
Price reaction · baseline $37.2 (2023-07-12 close) · hit pre-market · 2 other CODX headline(s) in the window, move may be shared
day 0 close
+10.5%
day 1
+8.9%
day 3 · peak
+13.7%
Market Sentiment Analysis
POSITIVE FACTORS
Co-Dx™ received significant funding of $1.2 million.
The funding supports the development of a multiplex test.
The test targets multiple respiratory viruses, including COVID-19.
Full Press Release Details
The U.S. National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx) Tech program has awarded Co-Dx™ $1.2 million to complete the development of its upper respiratory panel.
The multiplex test for influenza A/B, COVID-19, and respiratory syncytial virus runs on the firm’s Co-Dx PCR Home™ Testing Platform. Co-Dx will use the RADx funding to finish the assay’s development and prepare for clinical trials.